

9th AZ-KHIDI Topics of interests

- Multi-omics evaluation to predict clinical outcome
- IO responses in human ex vivo fragment models which can correlate with patient response
- Investigation of mechanisms to improve antigen presentation on tumour cells
- Developing predictive signatures of topoisomerase 1 inhibitor response
- Research related to TIM3, TIGIT, and post PD-1 therapy in HCC, BTC and Gastric cancer
- Impact of IO treatment on TME in Gastric cancer (HER2 negative)
- Pre-clinical models derived from early-stage disease, relapse on adjuvant therapy, specific genotypes
- DDR resistance mechanisms in multiple tumor types – Breast, Prostate, Pancreas and Ovary



2022 AZ Molecule Lists

Compound	Mechanism of Action
Olaparib	Poly (ADP-ribose) polymerase (PARP) inhibitor
Osimertinib	Epidermal growth factor receptor (EGFR) inhibitor
Savolitinib	cMET tyrosine kinase inhibitor
Capivasertib	AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor
Durvalumab	anti PD-L1 monoclonal antibody
Oleclumab	anti CD73 monoclonal antibody
Monalizumab	anti NKG2A monoclonal antibody
AZ6102	Tankyrase 1 and 2 inhibitor (TNKS1/2) inhibitor
AZD5305	Selective PARP1 inhibitor
AZD6738	Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase inhibitor
AZD1390	Ataxia telangiectasia mutated (ATM)-BBB
AZD2811	Aurora B serine/threonine kinase inhibitor
AZD0466	BCL2/xL inhibitor (nanomedicine)
AZD4573	Cyclin-dependent kinase 9(CDK9) inhibitor
AZD9833	Selective estrogen receptor degrader (SERD)
AZD8701	Forkhead-box P3 Transcription Factor Anti-Sense Oligonucleotide
AZD8055	Mammalian target of rapamycin (mTOR) kinase (TORC1/2) inhibitor
BCL6 PROTAC	BCL6 PROTAC

For more information: <https://www.astrazeneca.com/our-therapy-areas/pipeline.html>

